Neoadjuvant Immune Checkpoint Blockade: A Window into Treatment Response and Pri
PharmaTalkRadio13 Tammi 2023

Neoadjuvant Immune Checkpoint Blockade: A Window into Treatment Response and Pri

Neoadjuvant (pre-surgical) immune checkpoint blockade may prevent cancer relapse and progression.This treatment approach is now FDA-approved for resectable triple-negative breast cancer, and hundreds of clinical trials in other cancers are ongoing.Surgical resection specimens collected after several weeks of neoadjuvant ICB offer vast opportunities for predictive biomarker discovery and understanding ICB response/resistance. Suzanne Topalian, MD, Associate Director / Professor of Surgery, Bloomberg~Kimmel Institute for Cancer Immunotherapy / Johns Hopkins University Learn more about the IO360° Summit at www.io360summit.com

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(461)

Suosittua kategoriassa Tiede

tiedekulma-podcast
utelias-mieli
rss-mita-tulisi-tietaa
rss-duodecim-lehti
rss-hereilla
docemilia
rss-kasvikutsut
rss-vaasan-yliopiston-podcastit
rss-poliisin-mieli
rss-kasvatuspsykologiaa-kaikille